Wednesday, June 10, 2026
🇺🇸 FDA

Intelligence · Patents

Patents expiring in 2044

Annual patent cliff calendar for 2044 — US pharmaceutical patents by expiration date.

Patents
1,766

Quick answer

1,766 indexed pharmaceutical patents have expiration dates in 2044. Browse by soonest expiry with links to assignee companies and related drugs.

  1. US 12090209

    Twin base linkers for virus inactivation

    Northwestern University · Granted Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12090227

    Method to improve the encapsulation efficiency and physicochemical stability of ginsenosides Rg3 and CK nano-emulsion

    STANDARD FOODS (CHINA) CO., LTD · Granted Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12091386

    D-amphetamine compounds, compositions, and processes for making and using the same

    Zevra Therapeutics, Inc. · Granted Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12091410

    Heterocyclic compound

    Takeda Pharmaceutical Company Limited · Granted Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12091411

    IRAK degraders and uses thereof

    Kymera Therapeutics, Inc. · Granted Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12091666

    Xanthine dehydrogenase (XDH) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12091661

    Organic compositions to treat HSF1-related diseases

    Arrowhead Pharmaceuticals, Inc. · Granted Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12091692

    PH20 polypeptide variants, formulations and uses thereof

    HALOZYME, INC. · Granted Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 12090126

    Methods of administering solriamfetol to lactating women

    AXSOME MALTA LTD. · Granted Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 12090206

    Compositions comprising tri- and penta-block synthetic copolypeptide hydrogels

    The Regents of the University of California · Granted Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 12090140

    Non-sedating dexmedetomidine treatment regimens

    BioXcel Therapeutics, Inc. · Granted Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 12091675

    Gene therapy of hemophilia a using viral vectors encoding recombinant FVIII variants with increased expression

    Takeda Pharmaceutical Company Limited · Granted Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 12091407

    Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof

    VTV THERAPEUTICS LLC · Granted Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 12090139

    Formulations comprising triptan compounds

    Tonix Medicines, Inc. · Granted Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 12091387

    Quinoline cGAS antagonist compounds

    The Board of Regents of the University of Texas System · Granted Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 12090201

    Methods for treating atopic dermatitis by administering an IL-4R antagonist antibody

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 12089574

    Humanized skeletal muscle

    Regents of the University of Minnesota · Granted Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 12091463

    Clec9A binding agents comprising a recombinant heavy-chain only antibody (VHH)

    Orionis Biosciences, Inc · Granted Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 12091460

    Use of bispecific antigen-binding molecules that bind MUC16 and CD3 in combination with 4-1BB co-stimulation

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 12091437

    Molecules for organelle-specific protein delivery

    Larimar Therapeutics, Inc. · Granted Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 12090142

    Combination therapy for the treatment of cancer

    The Board of Regents of the University of Texas System · Granted Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 12089575

    Genetically modified mouse that expresses humanized PD1 and PD-L1 proteins

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 12091462

    Antibodies binding to vista at acidic pH

    Five Prime Therapeutics, Inc. · Granted Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 12090145

    Combination therapy for treating or preventing depression or other mood diseases

    United States Government as represented by the Department of Veterans Affairs · Granted Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. WO 2024188801

    UTILISATION DE LIGNÉES CELLULAIRES DE CAILLE POUR PRODUCTION DE POXVIRUS

    BAVARIAN NORDIC AS [DK] · Granted Thu Sep 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Sep 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 2024307628

    SYSTEMS AND METHODS FOR DELIVERY OF LIQUID PHARMACEUTICAL COMPOSITIONS IN PARTICULAR COMPRISING ONE OR MORE SGLT-2 INHIBITOR(S)

    BOEHRINGER INGELHEIM VETMEDICA GMBH [DE] · Granted Thu Sep 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Sep 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. WO 2024188803

    PRODUCTION DE POXVIRUS À PARTIR DE CULTURES DE CELLULES DE CAILLE

    BAVARIAN NORDIC AS [DK] · Granted Thu Sep 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Sep 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. WO 2024188802

    PROCÉDÉS D'ISOLEMENT DE POXVIRUS À PARTIR DE CULTURES DE CELLULES AVIAIRES

    BAVARIAN NORDIC AS [DK] · Granted Thu Sep 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Sep 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 12098116

    Crystalline prostacyclin (IP) receptor agonist and uses thereof

    United Therapeutics Corporation · Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 12097290

    Membrane encapsulated nanoparticles and method of use

    The Regents of the University of California · Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 12098138

    Substituted pyridinyl azetidinone derivatives for use in treating cancer and other diseases

    The Board of Regents of the University of Texas System · Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 12097261

    CDK2 degraders and uses thereof

    Kymera Therapeutics, Inc. · Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 12098118

    Analgesic and anti-addictive compositions for treatment of chronic pain and opioid addiction

    Regents of the University of Minnesota · Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 12097230

    Method and composition for treating post operative conditions

    Bright Green Corporation · Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 12098155

    Tebipenem pivoxil crystalline forms, compositions including the same, methods of manufacture, and methods of use

    SPERO THERAPEUTICS, INC. · Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 12098215

    Fusion protein construct

    Northwestern University · Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 12098144

    Piperazine indazole glucocorticoid receptor antagonists

    Corcept Therapeutics Incorporated · Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 12098152

    Methods and compositions for treating polycystic ovary syndrome

    SPRUCE BIOSCIENCES, INC. · Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 12097306

    Conformal coating of biological surfaces

    Takeda Pharmaceutical Company Limited · Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 12096754

    Non-human animals having a humanized lymphocyte-activation gene 3

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 12097223

    Mesenchymal stromal cells and uses related thereto

    Astellas Institute for Regenerative Medicine · Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 12097263

    Muscle targeting complexes and uses thereof for treating myotonic dystrophy

    Dyne Therapeutics, Inc. · Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 12097262

    mTORC1 inhibitors

    The Regents of the University of California · Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 12097196

    Dopamine D3 receptor selective antagonists/partial agonists and uses thereof

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 12098141

    Bicyclic indazole glucocorticoid receptor antagonists

    Corcept Therapeutics Incorporated · Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 12097213

    Sequential treatment of cancers using 6-thio-dG, checkpoint inhibitors and radiation therapy

    The Board of Regents of the University of Texas System · Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 12097291

    Thermostable vaccine compositions and methods of preparing same

    The Regents of the University of Colorado, a Body Corporate · Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 12097219

    Single-domain antibodies against CLL1 and constructs thereof

    Legend Biotech Ireland Limited · Granted Tue Sep 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many pharma patents expire in 2044?

1,766 published patents in our USPTO index have expiration dates falling in calendar year 2044.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.